Agrin and CD34 Immunohistochemistry for the Discrimination of Benign Versus Malignant Hepatocellular Lesions
Authors:
- Péter TátraiPTPéter Tátrai
- Áron SomoráczÁSÁron Somorácz
- Enkhjargal BatmunkhEBEnkhjargal Batmunkh
- Peter SchirmacherPSPeter Schirmacher
- András KissAKAndrás Kiss
- Zsuzsa SchaffZSZsuzsa Schaff
- Péter NagyPNPéter Nagy
- Ilona KovalszkyIKIlona Kovalszky
- 1 June 2009
- journal article
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
- Vol. 33 (6) , 874-885
Abstract
Agrin is a recently identified proteoglycan component of vascular and bile duct basement membranes in the liver. The selective deposition of agrin in hepatocellular carcinoma (HCC) microvessels versus sinusoidal walls prompted us to investigate the utility of agrin immunohistochemistry (IHC) in detecting malignant hepatocellular lesions. We focused on the differential diagnostic problems often presented by hepatocellular adenomas (HCAs) and dysplastic nodules. IHC for agrin was performed on 138 formalin-fixed, paraffin-embedded surgical specimens from 93 patients, including cirrhotic liver tissues (25), focal nodular hyperplasia (10), large regenerative nodules (8), low-grade (23) and high-grade (7) dysplastic nodules, small HCC (8), HCC (27), and HCA (30). Agrin immunostaining was compared with that of CD34 and, in selected cases, to glypican-3. The combination of agrin and CD34 sensitively (0.94) and specifically (0.93) identified lesions judged previously as malignant by histology. The majority of benign lesions were clearly agrin-negative, whereas the strength and extent of agrin IHC faithfully reflected dysplasia in “atypical” HCAs and in high-grade dysplastic nodules. Malignant lesions were uniformly positive. In conclusion, as agrin is highly selective for tumor blood vessels, IHC for agrin facilitates the discrimination of benign and malignant hepatocellular lesions. Moreover, whereas glypican-3 in some HCCs may appear in few scattered cells only, agrin is diffusely deposited in virtually all malignant lesions, which may prove advantageous in the evaluation of small specimens such as core biopsies.Keywords
This publication has 24 references indexed in Scilit:
- Glypican 3 Expression in Human Nonneoplastic, Preneoplastic, and Neoplastic TissuesAmerican Journal of Clinical Pathology, 2008
- Distinction of Hepatocellular Carcinoma From Benign Hepatic Mimickers Using Glypican-3 and CD34 ImmunohistochemistryAmerican Journal of Surgical Pathology, 2008
- Comparison of the expression of agrin, a basement membrane heparan sulfate proteoglycan, in cholangiocarcinoma and hepatocellular carcinomaHuman Pathology, 2007
- Pathological diagnosis of liver cell adenoma and focal nodular hyperplasia: Bordeaux updateJournal of Hepatology, 2007
- Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosisHepatology, 2007
- Treatment of hepatocellular carcinomaCritical Reviews in Oncology/Hematology, 2006
- Leberparenchymknoten bei pathologischer hepatischer Vaskularisation/PerfusionDer Pathologe, 2006
- Regeneration of hepatocyte ‘buds’ in cirrhosis from intrabiliary stem cellsJournal of Hepatology, 2003
- Glypican-3: a novel serum and histochemical marker for hepatocellular carcinomaGastroenterology, 2003
- Progenitor cells of the biliary epithelial cell lineageSeminars in Cell & Developmental Biology, 2002